Methylphenidate, modafinil, and caffeine for cognitive enhancement in chess: A double-blind, randomised controlled trial

European Neuropsychopharmacology

Volumn 27, Issue 3, 2017, Pages 248-260

  Franke, Andreas G ^a,d   Gränsmark, Patrik ^b   Agricola, Alexandra ^a   Schühle, Kai ^a   Rommel, Thilo ^a,e   Sebastian, Alexandra ^a   Balló, Harald E ^a,f   Gorbulev, Stanislav ^a   Gerdes, Christer ^b   Frank, Björn ^c   Ruckes, Christian ^a   Tüscher, Oliver ^a   Lieb, Klaus ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b STOCKHOLM UNIVERSITY   (Sweden)

^c UNIVERSITY OF KASSEL   (Germany)

^d Hochschule Neubrandenburg   (Germany)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

^f Internistische Gemeinschaftspraxis   (Germany)

Author keywords

Caffeine; Chess; Cognitive enhancement; Methylphenidate; Modafinil; Stimulants

Indexed keywords

CAFFEINE; METHYLPHENIDATE; MODAFINIL; PLACEBO; BENZHYDRYL DERIVATIVE; CENTRAL STIMULANT AGENT; WAKEFULNESS PROMOTING AGENT;

ADULT; AGITATION; ALERTNESS; ARTICLE; ATHLETE; CHESS; COGNITION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DECISION MAKING; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; EXECUTIVE FUNCTION; HEADACHE; HUMAN; MALE; MENTAL PERFORMANCE; NEUROPSYCHOLOGICAL TEST; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SELF CONCEPT; SIDE EFFECT; SKILL; SLEEP DISORDER; SPORT; ANALYSIS OF VARIANCE; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; DRUG EFFECT; FEMALE; MIDDLE AGED; RETROSPECTIVE STUDY;

ADULT; ANALYSIS OF VARIANCE; BENZHYDRYL COMPOUNDS; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; COGNITION; CROSS-SECTIONAL STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METHYLPHENIDATE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; RETROSPECTIVE STUDIES; WAKEFULNESS-PROMOTING AGENTS;

EID: 85009962807     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2017.01.006     Document Type: Article

References (101)

1. Arnsten, A.F., Stimulants: therapeutic actions in ADHD. Neuropsychopharmacol. 31:11 (2006), 2376–2383.
2. Atherton, M., Zhuang, J., Bart, W.M., Hu, X., He, S., A functional MRI study of high-level cognition. I. The game of chess. Cog. Brain Res. 16:1 (2003), 26–31.
3. Battleday, R.M., Brem, A.-K., Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: a systematic review. Eur. Neuropsychopharmacol. 25:11 (2015), 1865–1881.
4. Berg, E.A., A simple objective technique for measuring flexibility in thinking. J. Gen. Psychol. 39 (1948), 15–22.
5. Bilalić, M., Langner, R., Erb, M., Grodd, W., Mechanisms and neural basis of object and pattern recognition: a study with chess experts. J. Exp. Psychol.: General. 139:4 (2010), 728–742.
6. Bilalić, M., McLeod, P., Gobet, F., Specialization Effect and Its Influence on Memory and Problem Solving in Expert Chess Players. Cogn. Sci. 33:6 (2009), 1117–1143.
7. Bisagno, V., González, B., Urbano, F.J., Cognitive enhancers versus addictive psychostimulants: the good and bad side of dopamine on prefrontal cortical circuits. Pharmacol. Res. 109 (2016), 108–118.
8. Borota, D., Murray, E., Keceli, G., Chang, A., Watabe, J.M., Ly, M., Toscano, J.P., Yassa, M.A., Post-study caffeine administration enhances memory consolidation in humans. Nat. Neurosci. 17:2 (2014), 201–203.
9. Bostrom, N., Sandberg, A., Cognitive enhancement: methods, ethics, regulatory challenges. Sci. Eng. Ethics 15:3 (2009), 311–341, 10.1007/s11948-009-9142-5.
10. Brunstein, J.C., Heckhausen, H., Achievement motivation. Heckhausen, H., Heckhausen, J., (eds.) Motivation and Action, 2008, Cambridge University Press, Cambridge.
11. Burgard, D.A., Fuller, R., Becker, B., Ferrell, R., Dinglasan-Panlilio, M.J., Potential trends in Attention Deficit Hyperactivity Disorder (ADHD) drug use on a college campus: wastewater analysis of amphetamine and ritalinic acid. Sci. Total. Environ. 450-451 (2013), 242–249.
12. Campbell-Meiklejohn, D., Simonsen, A., Scheel-Kruger, J., Wohlert, V., Gjerloff, T., Frith, C.D., Rogers, R.D., Roepstorff, A., Moller, A., In for a penny, in for a pound: methylphenidate reduces the inhibitory effect of high stakes on persistent risky choice. J. Neurosci. 32:38 (2012), 13032–13038.
13. Campitelli, G., Gobet, F., Head, K., Buckley, M., Parker, A., Brain localization of memory chunks in chessplayers. Int. J Neurosci. 117:12 (2007), 1641–1659.
14. Caviola, L., Faber, N.S., Pills or push-ups? Effectiveness and public perception of pharmacological and non-pharmacological cognitive enhancement. Front. Psychol., 6(23), 2015, 435.
15. Chase, W.G., Simon, H.A., Perception in chess. Cogn. Psychol. 4 (1973), 55–81.
16. de Jongh, R., Bolt, I., Schermer, M., Olivier, B., Botox for the brain: enhancement of cognition, mood and pro-social behavior and blunting of unwanted memories. Neurosci. Biobehav. Rev. 32 (2008), 760–776.
17. Dietz, P., Striegel, H., Franke, A.G., Lieb, K., Simon, P., Ulrich, R., Randomized response estimates for the 12-month prevalence of cognitive-enhancing drug use in university students. Pharmacotherapy 33 (2013), 44–50.
18. Dinges, D.F., Powell, J.W., Microcomputer analyses of performance on a portable, simple visual RT task during sustained operations. Behav. Res. Methods Instr. Comp. 17 (1985), 652–655.
19. Diukova, A., Ware, J., Smith, J.E., Evans, C.J., Murphy, K., Rogers, P.J., Wise, R.G., Separating neural and vascular effects of caffeine using simultaneous EEG–FMRI: differential effects of caffeine on cognitive and sensorimotor brain responses. NeuroImage 62:1 (2012), 239–249.
20. Eagle, D.M., Tufft, Miles, R.A., Goodchild, H.L., Robbins, T.W., Differential effects of modafinil and methylphenidate on stop-signal reaction time task performance in the rat, and interactions with the dopamine receptor antagonist cis-flupenthixol. Psychopharmacology 192:2 (2007), 193–206.
21. Elo, A., The Rating of Chess Players. 1978, Past & Present. Arco Pub, New York.
22. Esposito, R., Cilli, F., Pieramico, V., Ferretti, A., Macchia, A., Tommasi, M., Saggino, A., Ciavardelli, D., Manna, A., Navarra, R., Cieri, F., Stuppia, L., Tartaro, A., Sensi, S.L., Harrison, B.J., Acute effects of modafinil on brain resting state networks in young healthy subjects. PLoS ONE, 8(7), 2013, e69224.
23. Farah, M.J., Illes, J., Cook-Deegan, R., Gardner, H., Kandel, E., King, P., Parens, E., Sahakian, B., Wolpe, P.R., Neurocognitive enhancement: what can we do and what should we do?. Nat. Rev. Neurosci. 5 (2004), 421–425.
24. FIDE position towards the World Anti Doping Agency Policy, 2014. (accessed in Dec at 〈http://www.fide.com/component/content/article/1-fide-news/7189-chess-wada-anti-doping-policy-nutrition-and-health.html〉).
25. Forlini, C., Hall, W., Maxwell, B., Outram, S.M., Reiner, P.B., Repantis, D., Schermer, M., Racine, E., Navigating the enhancement landscape. Ethical issues in research on cognitive enhancers for healthy individuals. EMBO Rep. 14 (2013), 123–128.
26. Franke, A.G., Bagusat, C., Dietz, P., Hoffmann, I., Simon, P., Ulrich, R., Lieb, K., Use of illicit and prescription drugs for cognitive or mood enhancement among surgeons. BMC Med., 11, 2013, 102.
27. Franke, A.G., Bagusat, C., Rust, S., Engel, A., Lieb, K., Substances used and prevalence rates of pharmacological cognitive enhancement among healthy subjects. Eur. Arch. Psychiatry Clin. Neurosci. 264:S1 (2014), S83–S90.
28. Franke, A.G., Bonertz, C., Christmann, M., Huss, M., Fellgiebel, A., Hildt, E., Lieb, K., Non-medical use of prescription stimulants and illicit use of stimulants for cognitive enhancement in pupils and students in Germany. Pharmacopsychiatry 44 (2011), 60–66.
29. Franke, A.G., Schwarze, C.E., Christmann, M., Bonertz, C., Hildt, E., Lieb, K., [Characteristics of university students using stimulants for cognitive enhancement: a pilot study]. Psychiat. Prax. 39 (2012), 174–180.
30. Franke, A.G., Soyka, M., [Pharmacological cognitive enhancement from a perspective of misuse and addiction]. Fortschr. Neurol. Psychiatr. 82 (2015), 83–90.
31. Gahr, M., Freudenmann, R.W., Hiemke, C., Kolle, M.A., Schonfeldt-Lecuona, C., Abuse of methylphenidate in Germany: data from spontaneous reports of adverse drug reactions. Psychiatry Res. 215 (2014), 252–254.
32. Gilleen, J., Michalopoulou, P.G., Reichenberg, A., Drake, R., Wykes, T., Lewis, S.W., Kapur, S., Modafinil combined with cognitive training is associated with improved learning in healthy volunteers – a randomised controlled trial. Eur. Neuropsychopharmacol. 24:4 (2014), 529–539.
33. Goldstein, R.Z., Volkow, N.D., Oral methylphenidate normalizes cingulate activity and decreases impulsivity in cocaine addiction during an emotionally salient cognitive task. Neuropsychopharmacology 36:1 (2011), 366–367.
34. Gobet, F., Expert memory: a comparison of four theories. Cognition 66:2 (1998), 115–152.
35. Gong, Y., Ericsson, K.A., Moxley, J.H., Canal-Bruland, R., Recall of briefly presented chess positions and its relation to chess skill. PLoS ONE, 10(3), 2015, e0118756.
36. Greely, H., Sahakian, B., Harris, J., Kessler, R.C., Gazzaniga, M., Campbell, P., Farah, M.J., Towards responsible use of cognitive-enhancing drugs by the healthy. Nature 456 (2008), 702–705.
37. Guida, A., Gobet, F., Tardieu, H., Nicolas, S., How chunks, long-term working memory and templates offer a cognitive explanation for neuroimaging data on expertise acquisition: a two-stage framework. Brain Cogn. 79:3 (2012), 221–244.
38. Haller, S., Rodriguez, C., Moser, D., Toma, S., Hofmeister, J., Sinanaj, I., Van De Ville, D., Giannakopoulos, P., Lovblad, K.-O., Acute caffeine administration impact on working memory-related brain activation and functional connectivity in the elderly: a BOLD and perfusion MRI study. Neuroscience 250 (2013), 364–371.
39. Hartgens, F., Kuipers, H., Effects of androgenic–anabolic steroids in athletes. Sports Med. 34 (2004), 513–554.
40. Healy, M.L., Gibney, J., Russell-Jones, D.L., Pentecost, C., Croos, P., Sonksen, P.H., Umpleby, A.M., High dose growth hormone exerts an anabolic effect at rest and during exercise in endurance-trained athletes. J. Clin. Endocrinol. Metab. 88 (2003), 5221–5226.
41. Hildt, E., Franke, A.G., Cognitive Enhancement - An Interdisciplinary Perspective. 2013, Springer-Verlag, Heidelberg, New York.
42. Hofstadter, D.R., Metamagical Themas: Questing for the Essence of Mind and Pattern. 1985, Basic Books, New York.
43. Holck, H.G.O., Effect of caffeine upon chess problem solving. J. Comp. Psychol. 15 (1933), 301–311.
44. Iversen, L., Speed, Ecstasy, Ritalin. Amphetamine – Theorie und Praxis. 2009, Verlag Hans Huber, Bern.
45. Joos, L., Goudriaan, A.E., Schmaal, L., van den Brink, W., Sabbe, B.G., Dom, G., Effect of modafinil on cognitive functions in alcohol dependent patients: a randomized, placebo-controlled trial. J. Psychopharmacol. 27:11 (2013), 998–1006.
46. Kahnemann, D., Thinking fast and slow. 2003, Farrar, Straus and Giroux Paperbacks, New York.
47. Kelley, A.M., Webb, C.M., Athy, J.R., Ley, S., Gaydos, S., Cognition enhancement by modafinil: a meta-analysis. Aviat. Space Environ. Med. 83 (2012), 685–690.
48. Killgore, W.D., Grugle, N.L., Killgore, D.B., Leavitt, B.P., Watlington, G.I., McNair, S., Balkin, T.J., Restoration of risk-propensity during sleep deprivation: caffeine, dextroamphetamine, and modafinil. Aviat. Space Environ. Med. 79 (2008), 867–874.
49. Killgore, W.D., Vo, A.H., Castro, C.A., Hoge, C.W., Assessing risk propensity in American soldiers: preliminary reliability and validity of the Evaluation of Risks (EVAR) scale – English version. Mil. Med. 171 (2006), 233–239.
50. Killgore, W.D., Kahn-Greene, E.T., Grugle, N.L., Killgore, D.B., Balkin, T.J., Sustaining executive functions during sleep deprivation: a comparison of caffeine, dextroamphetamine, and modafinil. Sleep 32:2 (2009), 205–216.
51. Klaassen, E.B., de Groot, R.H., Evers, E.A., Snel, J., Veerman, E.C., Ligtenberg, A.J., Jolles, J., Veltman, D.J., The effect of caffeine on working memory load-related brain activation in middle-aged males. Neuropharmacology 64 (2013), 160–167.
52. Koppelstaetter, F., Poeppel, T.D., Siedentopf, C.M., Ischebeck, A., Kolbitsch, C., Mottaghy, F.M., Felber, S., Jaschke, W.R., Krause, B.J., Caffeine and cognition in functional magnetic resonance imaging. J. Alzheimers Dis. 20:1 (2010), S71–S84.
53. Koppelstaetter, F., Poeppel, T.D., Siedentopf, C.M., Ischebeck, A., Verius, M., Haala, I., Mottaghy, F.M., Rhomberg, P., Golaszewski, S., Gotwald, T., Lorenz, I.H., Kolbitsch, C., Felber, S., Krause, B.J., Does caffeine modulate verbal working memory processes? An fMRI study. NeuroImage 39:1 (2008), 492–499.
54. Kuczenski, R., Segal, D.S., Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J. Neurochem. 68:5 (1997), 2032–2037.
55. Lejuez, C.W., Read, J.P., Kahler, C.W., Richards, J.B., Ramsey, S.E., Stuart, G.L., Strong, D.R., Brown, R.A., Evaluation of a behavioral measure of risk taking: the Balloon Analogue Risk Task (BART). J. Exp. Psychol. Appl., 8, 2002, 75.
56. Linssen, A.M., Sambeth, A., Vuurman, E.F., Riedel, W.J., Cognitive effects of methylphenidate in healthy volunteers: a review of single dose studies. Int. J. Neuropsychopharmacol. 17 (2014), 961–977.
57. Maher, B., Poll results: look who׳s doping. Nature 452 (2008), 674–675.
58. McCabe, S.E., West, B.T., Teter, C.J., Boyd, C.J., Trends in medical use, diversion, and nonmedical use of prescription medications among college students from 2003 to 2013: connecting the dots. Addict. Behav. 39:7 (2014), 1176–1182.
59. McNair, D.M., Lorr, M., Droppleman, L.F., Profile of mood states. 1971, Educational and Industrial Testing Service, San Diego.
60. Mehlman, M.J., Cognition-enhancing drugs. Milbank Q. 82 (2004), 483–506.
61. Mehta, M.A., Owen, A.M., Sahakian, B.J., Mavaddat, N., Pickard, J.D., Robbins, T.W., Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. J. Neurosci., 20(6), 2000, RC65.
62. Melara, R.D., Algom, D., Driven by information: a tectonic theory of Stroop effects. Psychol. Rev. 110:3 (2003), 422–471.
63. Mereu, M., Bonci, A., Newman, A.H., Tanda, G., The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders. Psychopharmacology 229:3 (2013), 415–434.
64. Minzenberg, M.J., Carter, C.S., Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology 33 (2008), 1477–1502.
65. Minzenberg, M.J., Yoon, J.H., Carter, C.S., Modafinil modulation of the default mode network. Psychopharmacology 215:1 (2011), 23–31.
66. Moeller, S.J., Honorio, J., Tomasi, D., Parvaz, M.A., Woicik, P.A., Volkow, N.D., Goldstein, R.Z., Methylphenidate enhances executive function and optimizes prefrontal function in both health and cocaine addiction. Cereb. Cortex 24:3 (2014), 643–653.
67. Moxley, J.H., Ericsson, K. Anders, Charness, N., Krampe, R.T., The role of intuition and deliberative thinking in experts׳ superior tactical decision-making. Cognition 124:1 (2012), 72–78.
68. Mulder, M.J., van Maanen, L., Forstmann, B.U., Perceptual decision neurosciences – a model-based review. Neuroscience 277 (2014), 872–884.
69. Müller, U., Rowe, J.B., Rittman, T., Lewis, C., Robbins, T.W., Sahakian, B.J., Effects of modafinil on non-verbal cognition, task enjoyment and creative thinking in healthy volunteers. Neuropharmacology 64 (2013), 490–495.
70. Postal, V., Inhibition of irrelevant information is not necessary to performance of expert chess players 1, 2. Percept. Mot. Skills 115:1 (2012), 60–68.
71. Pringle, A., Browning, M., Parsons, E., Cowen, P.J., Harmer, C.J., Early markers of cognitive enhancement: developing an implicit measure of cognitive performance. Psychopharmacology 230:4 (2013), 631–638.
72. Ragan, C.I., Bard, I., Singh, I., What should we do about student use of cognitive enhancers? An analysis of current evidence. Neuropharmacology 64 (2013), 588–595.
73. Randall, D.C., Shneerson, J.M., File, S.E., Cognitive effects of modafinil in student volunteers may depend on IQ. Pharmacol. Biochem. Behav. 82:1 (2005), 133–139.
74. Rasetti, R., Mattay, V.S., Stankevich, B., Skjei, K., Blasi, G., Sambataro, F., Arrillaga-Romany, I.C., Goldberg, T.E., Callicott, J.H., Apud, J.A., Weinberger, D.R., Modulatory effects of modafinil on neural circuits regulating emotion and cognition. Neuropsychopharmacology 35:10 (2010), 2101–2109.
75. Reitan, R.M., Wolfson, D., The Halstead–Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation, 2nd ed., 1993, Neuropsychology Press, South Tucson (Arizona).
76. Repantis, D., Schlattmann, P., Laisney, O., Heuser, I., Modafinil and methylphenidate for neuroenhancement in healthy individuals: a systematic review. Pharmacol. Res 62 (2010), 187–206.
77. Rubia, K., Halari, R., Cubillo, A., Mohammad, A.-M., Brammer, M., Taylor, E., Methylphenidate normalises activation and functional connectivity deficits in attention and motivation networks in medication-naïve children with ADHD during a rewarded continuous performance task. Neuropharmacology 57:7–8 (2009), 640–652.
78. Rubia, K., Halari, R., Cubillo, A., Smith, A.B., Mohammad, A.-M., Brammer, M., Taylor, E., Methylphenidate normalizes fronto-striatal underactivation during interference inhibition in medication-naïve boys with attention-deficit hyperactivity disorder. Neuropsychopharmacology 36:8 (2011), 1575–1586.
79. Sahakian, B.J., Bruhl, A.B., Cook, J., Killikelly, C., Savulich, G., Piercy, T., Hafizi, S., Perez, J., Fernandez-Egea, E., Suckling, J., Jones, P.B., The impact of neuroscience on society: cognitive enhancement in neuropsychiatric disorders and in healthy people. Philos. Trans. R. Soc. B, 370(1677), 2015, 20140214.
80. Sahakian, B.J., Morein-Zamir, S., Pharmacological cognitive enhancement: treatment of neuropsychiatric disorders and lifestyle use by healthy people. Lancet Psychiatry 2:4 (2015), 357–362.
81. Schlosberg, H., Three dimensions of emotion. Psychol. Rev. 61:2 (1954), 81–88.
82. Schmaal, L., Goudriaan, A.E., Joos, L., Krüse, A.M., Dom, G., van den Brink, Wim, Veltman, D.J., Modafinil modulates resting-state functional network connectivity and cognitive control in alcohol-dependent patients. Biol. Psychiatry 73:8 (2013), 789–795.
83. Schmaal, L., Joos, L., Koeleman, M., Veltman, D.J., van den Brink, Wim, Goudriaan, A.E., Effects of modafinil on neural correlates of response inhibition in alcohol-dependent patients. Biol. Psychiatry 73:3 (2013), 211–218.
84. Shallice, T., Specific impairments of planning. Philos. Trans. R. Soc. Lond. B Biol. Sci. 298:1089 (1982), 199–209.
85. Smith, M.E., Farah, M.J., Are prescription stimulants “smart pills”? The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals. Psychol. Bull., 137, 2011, 717.
86. Stahl, C., Voss, A., Schmitz, F., Nuszbaum, M., Tuscher, O., Lieb, K., Klauer, K.C., Behavioral components of impulsivity. J. Exp. Psychol. Gen. 143 (2014), 850–886.
87. Stroop, J.R., Studies of interference in serial verbal reactions. J. Exp. Psychol. 18 (1935), 643–662.
88. Sugden, C., Housden, C.R., Aggarwal, R., Sahakian, B.J., Darzi, A., Effect of pharmacological enhancement on the cognitive and clinical psychomotor performance of sleep-deprived doctors: a randomized controlled trial. Ann. Surg. 255 (2012), 222–227.
89. Turner, D.C., Robbins, T.W., Clark, L., Aron, A.R., Dowson, J., Sahakian, B.J., Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology 165:3 (2003), 260–269.
90. Unterrainer, J.M., Kaller, C.P., Halsband, U., Rahm, B., Planning abilities and chess: a comparison of chess and non-chess players on the Tower of London task. Br. J. Psychol. 97 (2006), 299–311.
91. Unterrainer, J.M., Kaller, C.P., Leonhart, R., Rahm, B., Revising superior planning performance in chess players: the impact of time restriction and motivation aspects. Am. J. Psychol. 124:2 (2011), 213–225.
92. van Maanen, L., Turner, B., Forstmann, B.U., From model-based perceptual decision-making to spatial interference control. Curr. Opin. Behav. Sci. 1 (2015), 72–77.
93. van Harreveld, F., Wagenmakers, E.-J., van der Maas, Han, L.J., The effects of time pressure on chess skill: an investigation into fast and slow processes underlying expert performance. Psychol. Res. 71:5 (2007), 591–597.
94. Volkow, N.D., Wang, G., Fowler, J.S., Logan, J., Gerasimov, M., Maynard, L., Ding, Y., Gatley, S.J., Gifford, A., Franceschi, D., Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J. Neurosci., 21(2), 2001, RC121.
95. Volkow, N.D., Wang, G.-J., Kollins, S.H., Wigal, T.L., Newcorn, J.H., Telang, F., Fowler, J.S., Zhu, W., Logan, J., Ma, Y., Pradhan, K., Wong, C., Swanson, J.M., Evaluating Dopamine Reward Pathway in ADHD. JAMA, 302(10), 2009, 1084.
96. Wesensten, N.J., Killgore, W.D., Balkin, T.J., Performance and alertness effects of caffeine, dextroamphetamine, and modafinil during sleep deprivation. J. Sleep Res. 14 (2005), 255–266.
97. Wilens, T.E., Adler, L.A., Adams, J., Sgambati, S., Rotrosen, J., Sawtelle, R., Utzinger, L., Fusillo, S., Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J. Am. Acad. Child. Adolesc. Psychiatry 47 (2008), 21–31.
98. Winder-Rhodes, S., Chamberlain, S., Idris, M., Robbins, T., Sahakian, B., Muller, U., Effects of modafinil and prazosin on cognitive and physiological functions in healthy volunteers. J. Psychopharmacol. 24:11 (2010), 1649–1657.
99. Wood, S., Sage, J.R., Shuman, T., Anagnostaras, S.G., Psychostimulants and cognition: a continuum of behavioral and cognitive activation. Pharmacol. Rev. 66:1 (2013), 193–221.
100. Wright, M.J., Gobet, F., Chassy, P., Ramchandani, P.N., ERP to chess stimuli reveal expert-novice differences in the amplitudes of N2 and P3 components. Psychophysiology 50:10 (2013), 1023–1033.
101. Zack, M., Poulos, C., Effects of the atypical stimulant modafinil on a brief gambling episode in pathological gamblers with high vs. low impulsivity. J. Psychopharmacol. 23:6 (2009), 660–671.